Atopic Dermatitis

In this article, the pathogenesis of atopic dermatitis and the role of weakened skin barrier and inflammation is discussed in detail. Potential treatment and management strategies that address this problem, and the benefits of this approach are highlighted.

Atopic dermatitis (AD) is a chronic, waxing and waning, often symmetric inflammatory eruption that is characterized by pruritus and xerosis. This article discusses the role of creams in normalizing the barrier function early, and preventing inflammation processes from starting.

This article reviews atopic dermatitis, and its shift in the philosophy behind treatment and management. Preventative therapy, long-term strategy, and focus on quality of life.

Atopic eczema is a chronic condition and a long view is necessary for disease control and management. This article discusses the important role of the skin barrier and how it may be a target for therapeutics in treating atopic eczema.

Skin barrier differences and variations in the presentation of common dermatoses such as xerosis and atopic dermatitis (AD) have been reported in racial/ethnic Canadian patients. This review discusses skin barrier differences and explores the role of ceramide-containing skin care in promoting a healthy skin barrier and mitigating AD.

Tralokinumab is an effective and safe treatment for adult patients with moderate-to-severe AD. It may be used alone or in combination with TCS. This biologic can be considered first-line treatment after failure of or intolerance to topical therapies.